NRD
SUPN icon

Nebula Research & Development’s Supernus Pharmaceuticals SUPN Stock Holding History

Nebula Research & Development’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,429
Closed -$392K – 772
2025
Q2 		$392K Buy
+12,429
New +$398K 0.03% 707

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nebula Research & Development's SUPN Position: Q3 2025 in Review

Nebula Research & Development sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 12,429 shares — an estimated $392K sold.

Nebula Research & Development first reported a position in SUPN in Q2 2025 and held it in 1 quarter. The position peaked at $392K in Q2 2025. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Nebula Research & Development reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 12,429 Supernus Pharmaceuticals shares in Q3 2025, an estimated $392K.
  • Nebula Research & Development first reported a position in Supernus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's Supernus Pharmaceuticals position peaked at $392K in Q2 2025.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.